AUG 25, 2020 10:25 AM PDT

FDA Approves Cannabis Drug to Treat Rare Genetic Disease

WRITTEN BY: Annie Lennon

The US Food and Drug Administration has approved Epidiolex, a cannabidiol (CBD) oral solution, to treat seizures linked to tuberous sclerosis complex (TSC), a rare genetic disease that causes benign tumors to grow on the brain and other organs such as the eyes, heart, and lungs.

Occurring in around 1 in 6,000 people, TSC typically affects the central nervous system. Aside from seizures, it is also known to cause developmental delay and behavioral problems. 

Previously, Epidolex had been approved to treat seizures from two rare forms of epilepsy: Lennox-Gestaut syndrome (LGS) and Dravet syndrome (DS). It is also currently the only FDA-approved drug to contain a purified substance derived from cannabis.

Prior to approval, Epidolex underwent a randomized, double-blind, placebo-controlled trial where 148 patients out of 224 received the drug. The purpose of the study was to measure the difference from baseline in seizure frequency. 

In the end, the researchers found that patients treated with Epidolex had a significant reduction in the frequency of seizures during the treatment periods than those on the placebo. The effects were seen within eight weeks and remained throughout the 16-week treatment period. 

The most common side effects form the drug in patients with TSC included diarrhea, elevated liver enzymes, decreased appetite, fever, sleepiness, and vomiting. Less common side effects for patients, regardless of condition, include liver injury, reduced weight, anemia, and increased creatinine, a sign of impaired kidney function.  

Given its potential for negative side effects (findings from a human trial showing that between 5% and 20% of patients receiving the drug suffered from liver damage), extreme care is needed for those who take it. As such, after prescription by a physician, parents, caregivers, and families are advised to monitor any unusual changes in mood or behavior, including worsening depression and suicidal thoughts, among those taking the drug. 

 

Sources: LabRootsMedical News

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
JUN 02, 2020
Cannabis Sciences
Ancient Israelites Used Cannabis to Experience God
JUN 02, 2020
Ancient Israelites Used Cannabis to Experience God
Researchers have found evidence that ancient worshipers in Israel may have used cannabis to experience God over 2800 yea ...
JUN 10, 2020
Cannabis Sciences
Cannabis Temporarily Relieves PTSD Symptoms
JUN 10, 2020
Cannabis Temporarily Relieves PTSD Symptoms
PTSD (Post Traumatic Stress Disorder) is a mental disorder characterized by flashbacks, nightmares, and severe anxiety f ...
JUN 23, 2020
Health & Medicine
New Evidence Medical Cannabis Can Lead to Decreased Opioid Use in Chronic Pain
JUN 23, 2020
New Evidence Medical Cannabis Can Lead to Decreased Opioid Use in Chronic Pain
For people with long term ongoing pain, medical cannabis is a valid option that could pave the way to reduced use of opi ...
JUN 24, 2020
Health & Medicine
Best Not Get Behind the Wheel After Indulging in Recreational Marijuana
JUN 24, 2020
Best Not Get Behind the Wheel After Indulging in Recreational Marijuana
Two new studies examining the effects of recreational marujiana on road deaths have been published in the June issue of ...
JUL 07, 2020
Cannabis Sciences
Marijuana Users are Better at Sticking to a Fitness Program
JUL 07, 2020
Marijuana Users are Better at Sticking to a Fitness Program
Forget the go-to stereotype of a lazy stoner. In fact, older people who consume marijuana are more, not less, likely to ...
AUG 04, 2020
Neuroscience
What happens in the Brain in Cannabis Cravers?
AUG 04, 2020
What happens in the Brain in Cannabis Cravers?
Marijuana is sometimes used to help people wean themselves off other drugs addictions, such as to opioids, but can also ...
Loading Comments...